Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its price target hoisted by The Goldman Sachs Group from $200.00 to $225.00 in a research report released on Thursday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology company's stock.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an "overweight" rating in a research note on Thursday. TD Cowen decreased their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Wedbush reissued an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. Finally, Stifel Nicolaus lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $193.43.

Ascendis Pharma A/S Trading Up 1.1 %

Shares of NASDAQ ASND traded up $1.59 during midday trading on Thursday, reaching $144.08. The company's stock had a trading volume of 551,280 shares, compared to its average volume of 433,669. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of -17.83 and a beta of 0.64. The stock has a 50 day simple moving average of $132.41 and a 200-day simple moving average of $132.34.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, equities analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ASND. T. Rowe Price Investment Management Inc. raised its stake in Ascendis Pharma A/S by 54.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock valued at $375,226,000 after purchasing an additional 960,504 shares in the last quarter. Capital International Investors raised its stake in Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after purchasing an additional 753,859 shares in the last quarter. Groupama Asset Managment acquired a new position in Ascendis Pharma A/S during the third quarter worth about $60,000. RA Capital Management L.P. raised its stake in Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after acquiring an additional 402,316 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after acquiring an additional 267,881 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.